Celltrion, Inc. (KRX:068270)

Market Cap	39.03T
Revenue (ttm)	2.88T
Net Income (ttm)	187.10B
Shares Out	212.12M
EPS (ttm)	933.64
PE Ratio	197.08
Forward PE	34.00
Dividend	714.29 (0.39%)
Ex-Dividend Date	Dec 27, 2024

Volume	1,175,987
Average Volume	609,117
Open	181,100
Previous Close	182,700
Day's Range	181,000 - 186,900
52-Week Range	152,667 - 200,952
Beta	0.08
RSI	54.91
Earnings Date	Feb 20, 2025

About Celltrion

Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 th...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 2,391
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 068270

Financial Performance

In 2023, Celltrion's revenue was 2.18 trillion, a decrease of -4.71% compared to the previous year's 2.28 trillion. Earnings were 535.65 billion, a decrease of -0.41%.